Format

Send to

Choose Destination
Cancer Treat Rev. 2019 Jan;72:56-64. doi: 10.1016/j.ctrv.2018.11.004. Epub 2018 Dec 1.

Proton therapy for treatment of intracranial benign tumors in adults: A systematic review.

Author information

1
Radiation Oncology Department, Centre François Baclesse, Caen, France; Archade, Advanced Resource Center for Hadrontherapy in Europe, Caen, France; LARIA, CEA, CIMAP-GANIL, Caen, France; Radiation Oncology Department, Institut Curie, Paris, France; Proton Therapy Center, Institut Curie, Orsay, France; Normandy University, Université de Caen Basse Normandie, Caen, France. Electronic address: Paul.Lesueur89@gmail.com.
2
Radiation Oncology Department, Institut Curie, Paris, France; Proton Therapy Center, Institut Curie, Orsay, France.
3
Proton Therapy Center, Institut Curie, Orsay, France.
4
Radiation Oncology Department, Centre François Baclesse, Caen, France; Archade, Advanced Resource Center for Hadrontherapy in Europe, Caen, France.
5
Radiation Oncology Department, Institut Curie, Paris, France.
6
Normandy University, Université de Caen Basse Normandie, Caen, France; Neurosurgery Department, CHU de Caen, France.
7
Normandy University, Université de Caen Basse Normandie, Caen, France; Endocrinology Department, CHU de Caen, France.
8
Radiation Oncology Department, Centre François Baclesse, Caen, France; Archade, Advanced Resource Center for Hadrontherapy in Europe, Caen, France; Normandy University, Université de Caen Basse Normandie, Caen, France.
9
Laboratoire de Physique Corpusculaire, Caen, France.
10
Radiation Oncology Department, Centre François Baclesse, Caen, France; Archade, Advanced Resource Center for Hadrontherapy in Europe, Caen, France; Normandy University, Université de Caen Basse Normandie, Caen, France; Laboratoire de Physique Corpusculaire, Caen, France.

Abstract

INTRODUCTION:

The depth-dose distribution of a proton beam, materialized by the Bragg peak makes it an attractive radiation modality as it reduces exposure of healthy tissues to radiations, compared with photon therapy Prominent indications, based on a long-standing experience are: intraocular melanomas, low-grade skull-base and spinal canal malignancies. However, many others potential indications are under investigations such as the benign morbid conditions that are compatible with an extended life-expectancy: low grade meningiomas, paragangliomas, pituitary adenomas, neurinomas craniopharyngioma or recurrent pleomorphic adenomas.

MATERIALS:

Given the radiation-induced risk of secondary cancer and the potential neurocognitive and functional alteration with photonic radiotherapy, we systematically analyzed the existing clinical literature about the use of proton therapy as an irradiation modality for cervical or intracranial benign tumors. The aim of this review was to report clinical outcomes of adult patients with benign intracranial or cervical tumors treated with proton therapy and to discuss about potential advantages of proton therapy over intensity modulated radiotherapy or radiosurgery.

RESULTS:

Twenty-four studies were included. There was no randomized studies. Most studies dealt with low grade meningiomas (n = 9). Studies concerning neurinoma (n = 4), pituitary adenoma (n = 5), paraganglioma (n = 5), or craniopharyngioma (n = 1) were fewer. Whatever the indication, long term local control was systematically higher than 90% and equivalent to series with conventional radiotherapy.

CONCLUSION:

Proton-therapy for treatment of adult benign intracranial and cervical tumors is safe. Randomized or prospective cohorts with long term cognitive evaluations are needed to assess the real place of proton-therapy in the treatment of adults benign head and neck tumors.

KEYWORDS:

Benign meningioma; Neurinoma; Para ganglioma; Pituitary adenoma; Proton therapy

PMID:
30530009
DOI:
10.1016/j.ctrv.2018.11.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center